Biopharma AI
ByIs AI Becoming Big Pharma’s Frontline Tool for Early Cancer Detection? Bristol Myers Squibb and Microsoft Signal a Strategic Shift
Executive Summary Bristol Myers Squibb (BMS) has entered a strategic partnership with Microsoft to advance AI-driven early detection…
How Will Hippocratic AI Leverage Grove AI to Accelerate Trial Efficiency and Patient Engagement?
January 22, 2026 — Global — BioNexAI Market Insights reports that Hippocratic AI, a leading AI innovator, has…
Is AstraZeneca’s Acquisition of Modella AI at JPM 2026 a Signal That Pharma Is Internalizing AI for R&D?
Cambridge, U.K. | January 2026 AstraZeneca has taken a decisive step to deepen its artificial intelligence capabilities, announcing…
Is the $1 Billion Lilly–NVIDIA Alliance at JPM26 the Turning Point Where AI Becomes Industrial-Scale Drug Discovery?
San Francisco | January 12, 2026 The 44th Annual J.P. Morgan Healthcare Conference (JPM26) opened with a defining…
AI’s R&D Acceleration in Biopharma: Proven Power or Selective Promise?
AI is accelerating biopharma R&D where data abundance meets repeatable decisions—delivering 30-50% timeline compression in target ID and…
Agentic AI in Biopharma R&D: From Hype to Hierarchical Autonomy
Agentic AI shifts biopharma R&D from static predictions to dynamic, self-executing agent swarms that plan, act, validate, and…
